Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD—A Systematic Review
暂无分享,去创建一个
[1] D. Booth,et al. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes , 2016, Hepatology.
[2] M. Orešič,et al. Ceramides Dissociate Steatosis and Insulin Resistance in the Human Liver in Non-Alcoholic Fatty Liver Disease Short title : Ceramides in Human Non-Alcoholic Fatty Liver Disease , 2016 .
[3] L. Perrone,et al. TM6SF2 Glu167Lys polymorphism is associated with low levels of LDL‐cholesterol and increased liver injury in obese children , 2016, Pediatric obesity.
[4] Jonathan C. Cohen,et al. Inactivation of Tm6sf2, a Gene Defective in Fatty Liver Disease, Impairs Lipidation but Not Secretion of Very Low Density Lipoproteins* , 2016, The Journal of Biological Chemistry.
[5] Hongyu Zhao,et al. Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: A multiethnic study , 2016, Hepatology.
[6] European Association for the Study of the Liver,et al. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease , 2016, Obesity Facts.
[7] S. Kong,et al. I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease , 2015, Liver international : official journal of the International Association for the Study of the Liver.
[8] S. Sookoian,et al. The dual and opposite role of the TM6SF2‐rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta‐analysis , 2015, Hepatology.
[9] P. Calder,et al. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial. , 2015, Journal of hepatology.
[10] J. Hardies,et al. Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients , 2015, Liver international : official journal of the International Association for the Study of the Liver.
[11] G. Musso,et al. PNPLA3 rs738409 and TM6SF2 rs58542926 gene variants affect renal disease and function in nonalcoholic fatty liver disease , 2015, Hepatology.
[12] E. Bjornsson,et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.
[13] Liyong Pu,et al. PNPLA3 polymorphisms (rs738409) and non‐alcoholic fatty liver disease risk and related phenotypes: a meta‐analysis , 2015, Journal of gastroenterology and hepatology.
[14] A. Burt,et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. , 2015, Journal of hepatology.
[15] Mats Fredrikson,et al. Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.
[16] Shasha Zhang,et al. Association Between Patatin-Like Phospholipase Domain Containing 3 Gene (PNPLA3) Polymorphisms and Nonalcoholic Fatty Liver Disease: A HuGE Review and Meta-Analysis , 2015, Scientific Reports.
[17] M. Orho-Melander,et al. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2. , 2015, Journal of hepatology.
[18] S. Sookoian,et al. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity , 2015, Hepatology.
[19] Ningning Wang,et al. The rs738409 (I148M) variant of the PNPLA3 gene and cirrhosis: a meta-analysis , 2015, Journal of Lipid Research.
[20] H. Yki-Järvinen. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. , 2014, The lancet. Diabetes & endocrinology.
[21] A. Di Costanzo,et al. Non-alcoholic fatty liver disease, metabolic syndrome and patatin-like phospholipase domain-containing protein3 gene variants. , 2014, European journal of internal medicine.
[22] A. Hamsten,et al. TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content , 2014, Proceedings of the National Academy of Sciences.
[23] Gianluca Bontempi,et al. Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta‐analysis of individual participant data , 2014, Hepatology.
[24] Aijaz Ahmed,et al. Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations. , 2014, World journal of hepatology.
[25] He Zhang,et al. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk , 2014, Nature Genetics.
[26] J. Browning,et al. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. , 2014, Gastroenterology.
[27] Anne Tybjærg-Hansen,et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease , 2014, Nature Genetics.
[28] Rohit Loomba,et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials , 2013, Hepatology.
[29] Rohit Loomba,et al. The global NAFLD epidemic , 2013, Nature Reviews Gastroenterology &Hepatology.
[30] M. Taskinen,et al. A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population , 2013, Obesity.
[31] P. Bedossa,et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. , 2013, Journal of hepatology.
[32] R. Idilman,et al. Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy. , 2013, Radiology.
[33] G. Targher,et al. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis , 2013, Nature Reviews Gastroenterology &Hepatology.
[34] A. Gamst,et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. , 2013, Radiology.
[35] D. Brenner,et al. Association between novel MRI‐estimated pancreatic fat and liver histology‐determined steatosis and fibrosis in non‐alcoholic fatty liver disease , 2013, Alimentary pharmacology & therapeutics.
[36] Joan Tordjman,et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients , 2012, Hepatology.
[37] D. Brenner,et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non‐alcoholic fatty liver disease – MRI accurately quantifies hepatic steatosis in NAFLD , 2012, Alimentary pharmacology & therapeutics.
[38] K. Cusi,et al. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.
[39] Sarah A. Scott,et al. Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. , 2012, Cell metabolism.
[40] Meng-Su Zeng,et al. Standardized Ultrasound Hepatic/Renal Ratio and Hepatic Attenuation Rate to Quantify Liver Fat Content: An Improvement Method , 2011, Obesity.
[41] Shyi-Jang Shin,et al. The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population , 2011, Liver international : official journal of the International Association for the Study of the Liver.
[42] A. Gamst,et al. Reproducibility of MRI‐determined proton density fat fraction across two different MR scanner platforms , 2011, Journal of magnetic resonance imaging : JMRI.
[43] Eliseo Guallar,et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta‐analysis , 2011, Hepatology.
[44] Jonathan C. Cohen,et al. Expression and Characterization of a PNPLA3 Protein Isoform (I148M) Associated with Nonalcoholic Fatty Liver Disease* , 2011, The Journal of Biological Chemistry.
[45] S. Sookoian,et al. Meta‐analysis of the influence of I148M variant of patatin‐like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease , 2011, Hepatology.
[46] Mei-Hwei Chang,et al. A common variant in the PNPLA3 gene is a risk factor for non-alcoholic fatty liver disease in obese Taiwanese children. , 2011, The Journal of pediatrics.
[47] K. Vigen,et al. T1 independent, T2* corrected chemical shift based fat–water separation with multi‐peak fat spectral modeling is an accurate and precise measure of hepatic steatosis , 2011, Journal of magnetic resonance imaging : JMRI.
[48] B. Neuschwander‐Tetri,et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings , 2011, Hepatology.
[49] Scott B Reeder,et al. Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy. , 2011, Radiology.
[50] Nicholette D. Palmer,et al. Association of PNPLA3 with non‐alcoholic fatty liver disease in a minority cohort: the Insulin Resistance Atherosclerosis Family Study , 2011, Liver international : official journal of the International Association for the Study of the Liver.
[51] E. Brunt,et al. Histopathology of nonalcoholic fatty liver disease. , 2010, World journal of gastroenterology.
[52] A. Alisi,et al. I148M patatin‐like phospholipase domain‐containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease , 2010, Hepatology.
[53] B. Neuschwander‐Tetri. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites , 2010, Hepatology.
[54] V. M. Cambuli,et al. The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life. , 2010, Journal of hepatology.
[55] J. Stoker,et al. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis , 2010, European Radiology.
[56] Vincent Wai-Sun Wong,et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years , 2010, Gut.
[57] E. Bugianesi,et al. Homozygosity for the patatin‐like phospholipase‐3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease , 2010, Hepatology.
[58] Nick V. Grishin,et al. A Sequence Variation (I148M) in PNPLA3 Associated with Nonalcoholic Fatty Liver Disease Disrupts Triglyceride Hydrolysis , 2009, The Journal of Biological Chemistry.
[59] S. Grundy,et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As , 2009, Circulation.
[60] F. Schick,et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. , 2009, Journal of hepatology.
[61] F. Schick,et al. Dissociation Between Fatty Liver and Insulin Resistance in Humans Carrying a Variant of the Patatin-Like Phospholipase 3 Gene , 2009, Diabetes.
[62] Beverley Balkau,et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population , 2009, Hepatology.
[63] M. Ridderstråle,et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans , 2009, Diabetologia.
[64] C. Sirlin,et al. Fatty liver disease: MR imaging techniques for the detection and quantification of liver steatosis. , 2009, Radiographics : a review publication of the Radiological Society of North America, Inc.
[65] D. Chianese,et al. Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign? , 2008, Journal of Translational Medicine.
[66] Azmat Ali,et al. Magnetic resonance imaging and spectroscopy for monitoring liver steatosis , 2008, Journal of magnetic resonance imaging : JMRI.
[67] Alexander Pertsemlidis,et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease , 2008, Nature Genetics.
[68] A. Kotronen,et al. Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. , 2008, Gastroenterology.
[69] B. S. Mohammed,et al. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. , 2008, Gastroenterology.
[70] A. Kotronen,et al. Effect of liver fat on insulin clearance. , 2007, American journal of physiology. Endocrinology and metabolism.
[71] K. Pietiläinen,et al. Liver fat in the metabolic syndrome. , 2007, The Journal of clinical endocrinology and metabolism.
[72] Amalia Gastaldelli,et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. , 2007, Gastroenterology.
[73] S. Curley,et al. Comparison of CT methods for determining the fat content of the liver. , 2007, AJR. American journal of roentgenology.
[74] Irene M Stratton,et al. Comparison of 11 human insulin assays: implications for clinical investigation and research. , 2007, Clinical chemistry.
[75] Claudio Cobelli,et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men , 2006, Proceedings of the National Academy of Sciences.
[76] Sang Won Lee,et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. , 2006, Radiology.
[77] H. Hussain,et al. Hepatic fat fraction: MR imaging for quantitative measurement and display--early experience. , 2005, Radiology.
[78] O. Cummings,et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.
[79] J. Jessurun,et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.
[80] S. Grundy,et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. , 2005, American journal of physiology. Endocrinology and metabolism.
[81] H. Greene,et al. Fatty liver: Biochemical and clinical considerations , 1975, The American Journal of Digestive Diseases.
[82] C. Mottin,et al. The Role of Ultrasound in the Diagnosis of Hepatic Steatosis in Morbidly Obese Patients , 2004, Obesity surgery.
[83] R. Turner,et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.
[84] C. Ryan,et al. One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[85] A. Häkkinen,et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. , 2002, The Journal of clinical endocrinology and metabolism.
[86] M. Fishbein,et al. Rapid MRI using a modified Dixon technique: a non-invasive and effective method for detection and monitoring of fatty metamorphosis of the liver , 2001, Pediatric Radiology.
[87] F. Schick,et al. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. , 1999, American journal of physiology. Endocrinology and metabolism.
[88] P. Schmalbrock,et al. Introduction of fast MR imaging in the assessment of hepatic steatosis. , 1995, Magnetic resonance imaging.
[89] N. Rofsky,et al. Comparison between in-phase and opposed-phase T1-weighted breath-hold FLASH sequences for hepatic imaging. , 1996, Journal of computer assisted tomography.
[90] C. Thomsen,et al. Quantification of liver fat using magnetic resonance spectroscopy. , 1994, Magnetic resonance imaging.
[91] C. Tiribelli,et al. Fatty Infiltration of the Liver: Quantification by 1H Localized Magnetic Resonance Spectroscopy and Comparison with Computed Tomography , 1993, Investigative radiology.
[92] A. Joseph,et al. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. , 1991, Clinical radiology.
[93] B. Goldberg,et al. Sonography of diffuse benign liver disease: accuracy of pattern recognition and grading. , 1986, AJR. American journal of roentgenology.
[94] J. Maxwell,et al. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. , 1986, British medical journal.
[95] W. T. Dixon. Simple proton spectroscopic imaging. , 1984, Radiology.
[96] G. Bydder,et al. Computed tomography attenuation values in fatty liver. , 1981, The Journal of computed tomography.
[97] L Axel,et al. Difference between liver and spleen CT numbers in the normal adult: its usefulness in predicting the presence of diffuse liver disease. , 1980, Radiology.
[98] K. Dewbury,et al. The accuracy of ultrasound in the detection of fatty infiltration of the liver. , 1980, The British journal of radiology.
[99] K. Dewbury,et al. Ultrasound in the detection of chronic liver disease (the "bright liver"). , 1979, The British journal of radiology.
[100] H. Donhoffer. Quantitative estimation of lipids in needle biopsy sized specimens of cadaver liver. , 1974, Acta medica Academiae Scientiarum Hungaricae.
[101] A. Lundquist,et al. Lipid composition of human liver biopsy specimens. , 2009, Acta medica Scandinavica.